Healthcare - Oncology
Companies developing cancer therapeutics, diagnostics, and precision oncology tools
Immunotherapy & Immuno-Oncology78
Targeted Therapy & Precision Oncology95
Cell & Gene Therapy for Cancer35
Radiopharmaceuticals & ADCs11
Cancer Diagnostics & Biomarkers28
 LLY | Eli Lilly & Co. | Targeted Therapy & Precision Oncology | $1.1t | $1174.75 | +0.6% | 2.2M |
 JNJ | Johnson & Johnson | Immunotherapy & Immuno-Oncology | $0.6t | $253.31 | +1.1% | 7.5M |
 ABBV | ABBVIE INC. | Immunotherapy & Immuno-Oncology | $444.6b | $254.38 | +0.0% | 5.2M |
 MRK | Merck & Co., Inc. | Immunotherapy & Immuno-Oncology | $317.4b | $127.58 | +0.0% | 10.7M |
 AZN | AstraZeneca PLC | Immunotherapy & Immuno-Oncology | $294.1b | $168.30 | +0.2% | 1.8M |
 AMGN | Amgen Inc | Immunotherapy & Immuno-Oncology | $195.4b | $364.85 | -1.5% | 2.1M |
 GILD | Gilead Sciences Inc | Cell & Gene Therapy for Cancer | $156.9b | $134.40 | -1.5% | 5.1M |
 BMY | Bristol-Myers Squibb Co. | Immunotherapy & Immuno-Oncology | $117.7b | $60.89 | +0.5% | 9.8M |
 REGN | Regeneron Pharmaceuticals Inc | Immunotherapy & Immuno-Oncology | $65.4b | $676.50 | -0.3% | 479.2K |
 RVMD | Revolution Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $39.8b | $184.55 | +3.9% | 1.5M |
 NTRA | Natera, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $38.9b | $271.38 | +0.6% | 839.2K |
 MRNA | Moderna, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $27.8b | $61.87 | -2.1% | 3.9M |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Immunotherapy & Immuno-Oncology | $24.9b | $58.31 | -0.6% | 2.2M |
 INCY | Incyte Genomics Inc | Targeted Therapy & Precision Oncology | $22.6b | $117.64 | +0.5% | 1.6M |
 GH | Guardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $19.9b | $153.25 | +0.6% | 1.7M |
 JAZZ | Jazz Pharmaceuticals, Inc. | Targeted Therapy & Precision Oncology | $15.1b | $248.12 | +2.2% | 390.2K |
 EXEL | Exelixis Inc | Targeted Therapy & Precision Oncology | $13.7b | $55.80 | +0.4% | 1.7M |
 NUVL | Nuvalent, Inc. Class A Common Stock | Targeted Therapy & Precision Oncology | $9.8b | $123.96 | 0.0% | N/A |
 CORT | Corcept Therapeutics Inc. | Targeted Therapy & Precision Oncology | $9.3b | $90.55 | +0.8% | 855.8K |
 HALO | Halozyme Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $9.3b | $77.80 | +0.3% | 1.1M |
 IBRX | ImmunityBio, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $9.2b | $7.69 | +2.8% | 8.3M |
 LNTH | Lantheus Holdings, Inc | Radiopharmaceuticals & ADCs | $7.2b | $107.50 | +2.3% | 884.9K |
 ACLX | Arcellx, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $6.7b | $115.06 | -0.0% | 16.1M |
 COGT | Cogent Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $6.6b | $38.45 | +3.0% | 1.6M |
 CGON | CG Oncology, Inc. Common stock | Immunotherapy & Immuno-Oncology | $6.3b | $71.87 | +3.3% | 781.0K |
 ERAS | Erasca, Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.7b | $18.77 | +0.7% | 6.0M |
 BLLN | BillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & Biomarkers | $5.5b | $129.50 | +1.6% | 595.7K |
 CELC | Celcuity Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.1b | $89.25 | +0.2% | 1.2M |
 TNGX | Tango Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $5.1b | $29.02 | +3.1% | 2.0M |
 CAI | Caris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $5.0b | $16.73 | +0.0% | 2.8M |
 VCYT | Veracyte, Inc. | Cancer Diagnostics & Biomarkers | $4.7b | $58.91 | -0.1% | 932.9K |
 RLAY | Relay Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.1b | $19.89 | +2.8% | 1.8M |
 RCUS | Arcus Biosciences, Inc. | Immunotherapy & Immuno-Oncology | $3.9b | $27.36 | +2.7% | 610.0K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.6b | $36.75 | +0.2% | 793.2K |
 ELVN | Enliven Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.6b | $53.65 | +4.5% | 730.5K |
 ADPT | Adaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $3.4b | $22.84 | +3.7% | 2.8M |
 GRAL | GRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $2.9b | $71.52 | +0.8% | 322.1K |
 SLS | SELLAS Life Sciences Group, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $2.9b | $13.32 | +12.1% | 10.8M |
 NRIX | Nurix Therapeutics, Inc. Common stock | Targeted Therapy & Precision Oncology | $2.5b | $23.13 | +0.2% | 643.3K |
 IMNM | Immunome, Inc. | Targeted Therapy & Precision OncologyRadiopharmaceuticals & ADCs | $2.4b | $22.23 | +0.5% | 540.5K |
 ABCL | AbCellera Biologics Inc. Common Shares | Radiopharmaceuticals & ADCs | $2.4b | $6.48 | +5.0% | 4.1M |
 NTLA | Intellia Therapeutics, Inc | Cell & Gene Therapy for Cancer | $2.4b | $11.51 | -4.1% | 3.8M |
 NKTR | Nektar Therapeutics | Immunotherapy & Immuno-Oncology | $2.4b | $68.23 | +1.7% | 450.0K |
 BHVN | Biohaven Ltd. | Targeted Therapy & Precision Oncology | $2.2b | $15.39 | +9.0% | 3.2M |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.2b | $21.52 | -0.0% | 3.0M |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.0b | $25.00 | +6.0% | 1.1M |
 PGEN | Precigen, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $2.0b | $5.00 | 0.0% | 2.6M |
 NUVB | Nuvation Bio Inc. | Targeted Therapy & Precision Oncology | $2.0b | $5.83 | +2.8% | 3.3M |
 BCAX | Bicara Therapeutics Inc. Common Stock | Immunotherapy & Immuno-Oncology | $2.0b | $27.93 | +0.5% | 385.9K |
 SNDX | Syndax Pharmaceuticals, Inc. | Immunotherapy & Immuno-Oncology | $1.9b | $22.41 | +0.4% | 782.9K |